Hikal Ltd Stock Price Today (NSE: HIKAL)
Fundamental Score
Hikal Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Hikal Ltd share price today is ₹204.75, up +0.00% on NSE/BSE as of 20 February 2026. Hikal Ltd (HIKAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.80K (Cr). The 52-week high for HIKAL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 276.82x, HIKAL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.38% and a debt-to-equity ratio of 0.57.
Hikal Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Hikal Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Hikal Share Price Analysis: ROCE Efficiency and Competitive Positioning
The pharmaceutical industry is currently navigating a complex landscape, facing increasing regulatory scrutiny and pricing pressures, demanding exceptional operational efficiency for sustained profitability. This analysis examines the financial health of Hikal Ltd, focusing on its Return on Capital Employed (ROCE), and its impact on long-term value. Currently, the Hikal share price stands at ₹179.520004, reflecting market sentiment influenced by various factors including financial performance and sector trends. A key metric to analyze this market sentiment and the underlying fundamentals is ROCE.
Hikal Ltd's ROCE of 9.85% is a crucial indicator of how effectively the company is utilizing its capital to generate profits. While a positive ROCE is encouraging, its magnitude must be contextualized within the sector and compared to its peers. A higher ROCE generally suggests stronger capital management and a potential competitive advantage. However, compared to industry leaders and considering the capital-intensive nature of pharmaceutical manufacturing, 9.85% indicates room for improvement in asset utilization and profitability margins. The impact of this ROCE on Hikal's moat, or its sustainable competitive advantage, is significant. A consistently low ROCE can weaken the moat, making the company more susceptible to competition and pricing pressures.
In comparison, evaluating management quality becomes crucial. While data on specific management performance metrics requires deeper investigation, contrasting Hikal Ltd with peers like
Mankind Pharma Ltd regarding their operational efficiency and capital allocation strategies offers valuable insights. Mankind Pharma Ltd, for instance, may exhibit different levels of operational efficiency which translates into a different financial performance. Any difference between these companies could lead to a divergence in relative valuations based on investor sentiment.Ultimately, a robust ROCE is not just a number; it's a reflection of a company's ability to generate value for its shareholders and sustain its competitive position. A consistent and improving ROCE strengthens the investment case for Hikal Ltd, while a declining or stagnant ROCE raises concerns about its long-term prospects. This analysis is a component of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on quantifiable financial metrics. This observational financial analysis provides insights to help assess Hikal Ltd's strengths and weaknesses.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hikal Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HIKAL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Operating Margins (16.25%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Cash Generation (₹232.07 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (7.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.85%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 276.82x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-290.71%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-29.68%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (4.29% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-0.94% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.94% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.21x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 9.38%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Hikal Ltd Financial Statements
Comprehensive financial data for Hikal Ltd including income statement, balance sheet and cash flow
About HIKAL (Hikal Ltd)
Hikal Ltd (HIKAL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹2.80K (Cr). Hikal Ltd has delivered a Return on Equity (ROE) of 7.38% and a ROCE of 9.85%. The debt-to-equity ratio stands at 0.57, reflecting the company's capital structure. Investors tracking HIKAL share price can monitor key metrics including P/E ratio, promoter holding of 68.85%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
HIKAL Share Price: Frequently Asked Questions
What is the current share price of Hikal Ltd (HIKAL)?
As of 20 Feb 2026, 06:13 am IST, Hikal Ltd share price is ₹204.75. The HIKAL stock has a market capitalisation of ₹2.80K (Cr) on NSE/BSE.
Is HIKAL share price Overvalued or Undervalued?
HIKAL share price is currently trading at a P/E ratio of 276.82x, compared to the industry average of 31.77x. Based on this relative valuation, the Hikal Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of HIKAL share price?
The 52-week high of HIKAL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Hikal Ltd share price?
Key factors influencing HIKAL share price include quarterly earnings growth (Sales Growth: -29.68%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Hikal Ltd a good stock for long-term investment?
Hikal Ltd shows a 5-year Profit Growth of -0.94% and an ROE of 7.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.57 before investing in HIKAL shares.
How does Hikal Ltd compare with its industry peers?
Hikal Ltd competes with major peers in the Pharmaceuticals. Investors should compare HIKAL share price P/E of 276.82x and ROE of 7.38% against the industry averages to determine competitive standing.
What is the P/E ratio of HIKAL and what does it mean?
HIKAL share price has a P/E ratio of 276.82x compared to the industry average of 31.77x. Investors pay ₹277 for every ₹1 of annual earnings.
How is HIKAL performing according to Bull Run's analysis?
HIKAL has a Bull Run fundamental score of 20.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does HIKAL belong to?
HIKAL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Hikal Ltd share price.
What is Return on Equity (ROE) and why is it important for HIKAL?
HIKAL has an ROE of 7.38%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Hikal Ltd generates profits from shareholders capital.
How is HIKAL debt-to-equity ratio and what does it indicate?
HIKAL has a debt-to-equity ratio of 0.57, which indicates moderate leverage that should be monitored.
What is HIKAL dividend yield and is it a good dividend stock?
HIKAL offers a dividend yield of 0.62%, meaning you receive ₹0.62 annual dividend for every ₹100 invested in Hikal Ltd shares.
How has HIKAL share price grown over the past 5 years?
HIKAL has achieved 5-year growth rates of: Sales Growth 4.29%, Profit Growth -0.94%, and EPS Growth -0.94%.
What is the promoter holding in HIKAL and why does it matter?
Promoters hold 68.85% of HIKAL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Hikal Ltd.
What is HIKAL market capitalisation category?
HIKAL has a market capitalisation of ₹2796 crores, placing it in the Small-cap category.
How volatile is HIKAL stock?
HIKAL has a beta of N/A. A beta > 1 suggests the Hikal Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is HIKAL operating profit margin trend?
HIKAL has a 5-year average Operating Profit Margin (OPM) of 16.25%, indicating the company's operational efficiency.
How is HIKAL quarterly performance?
Recent quarterly performance shows Hikal Ltd YoY Sales Growth of -29.68% and YoY Profit Growth of -290.71%.
What is the institutional holding pattern in HIKAL?
HIKAL has FII holding of 4.23% and DII holding of 5.15%. Significant institutional holding often suggests professional confidence in the Hikal Ltd stock.